Research Archive — Page 68 of 138

December 14, 2021

Immune landscape in adrenal cancer

The profile of immune-related gene expression and tumor-infiltrating immune cells in adrenocortical cancer suggests targets for new treatment strategies.

By Leigh MacMillan
December 13, 2021

Oral microbes and gastric cancer

Studies in three large population cohorts that include Asian, African American and European American people support a role for the oral microbiota — the collection of microbial species in the mouth — in gastric cancer development.

By Leigh MacMillan
PHOTO: Members of the supermere discovery team include (front row from left) Qi Liu, PhD, Robert Coffey, MD, Qin Zhang, PhD, and (back row from left) James Higginbotham, PhD; Dennis Jeppesen, PhD; and Jeffrey Franklin, PhD. (hoto by Erin O. Smith)
December 10, 2021

“Supermeres” may carry clues to cancer, Alzheimer’s disease and COVID-19

Vanderbilt researchers have discovered a nanoparticle released from cells, called a “supermere,” which contains enzymes, proteins and RNA associated with multiple cancers, cardiovascular disease, Alzheimer’s disease and even COVID-19.

By Bill Snyder
December 9, 2021

Cell signaling targets in leukemia

Vanderbilt researchers identified a critical role for IL-1beta signaling in leukemia cells with a certain mutation, suggesting this pathway may be a good target for novel treatments.

By Leigh MacMillan
December 9, 2021

Prostate cancer treatment regret

Vanderbilt researchers suggest that to reduce treatment-related regret for men with localized prostate cancer, treatment preparation should focus on shared decision-making and aligning patient expectations with treatment toxicity.

By Leigh MacMillan
December 8, 2021

International study supports dupilumab for treatment of moderate-to-severe asthma in children

In a late-stage clinical trial, the biologic agent dupilumab reduced the rate of severe asthma attacks and improved lung function and asthma control for children ages 6 to 11 with moderate-to-severe asthma, offering a new option to these patients.

By Leigh MacMillan